Key Drivers
- Strong liquidity
- Deep losses
- Weak cash flow
AIAI Summary
RXRX has shifted from an “AI drug discovery” re-rating story to a capital-disciplined but still unproven execution story: the balance sheet and runway are solid, but investors now need clear clinical and revenue conversion evidence from the pipeline before the stock can re-rate, especially given lumpy collaboration revenue, ongoing cash burn, and weak price action.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •Deep losses
- •Weak cash flow
RXRX has a strong liquidity position with modest debt and ample cash, but persistent and worsening losses, deeply negative cash flow, and a high sales multiple make the stock look operationally risky despite its balance-sheet cushion.
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •Key support
- •Weak momentum
RXRX has been in a clear short-term downtrend over the last month, falling about 22% with lower highs/lows, while $2.93 is key support and $3.26–$3.32 is resistance.
Fell about 22% from $3.78 to $2.93 over the last month
Sentiment & News
Key News Insights:
- •Clinical Progress
- •Revenue Miss
- •Cash Burn
Recursion delivered some clinical and FDA progress, but weaker revenue, ongoing cash-burn concerns, and skeptical analyst sentiment kept investor pressure on the stock. ക
The news is mixed but currently leans negative, as pipeline milestones are not yet offsetting execution and financing concerns for the stock
Similar Companies in Healthcare
Other companies in the same sector with AI ratings